Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol Goes In Big On New Valentine Nektar

Executive Summary

Bristol paid a handsome $1.85bn upfront for access to Nektar's lead immuno-oncology program NKTR-214 to study in combination with its own drugs, but the expense was viewed by some as a smart play versus buying Nektar outright.

You may also be interested in...



Nektar Restructuring Ends Bempeg Ambitions, Cuts Staff By 70%

Following termination of its immuno-oncology partnership with Bristol, Nektar is paring operations, closing its India site and focusing on mid-stage NKTR-358, partnered with Lilly, and NKTR-255.

Nektar/BMS’s IL-2 Inhibitor Melanoma Failure Leaves Room For Other Contenders

Nektar is hoping the combination of bempegaldesleukin and Opdivo could have better chances in kidney and bladder cancers, but analysts aren’t sure and see other IL-2 therapeutics as having better prospects.

AstraZeneca’s Outlicensing Tactics Make It Top Dealmaker

Datamonitor report highlights big pharma’s licensing trends from last five years, and finds UK firm top on numbers of deals, but Merck & Co put up most money.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC100403

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel